Abstract Library

#4476 Pancreatic stellate cells promote tumorigenesis and progression of pancreatic neuroendocrine tumours through SERPINE2 and KCNA5

Introduction: Pancreatic stellate cells (PSC) are stromal cells in the pancreas that play a significant role in pancreatic pathology. Nevertheless, few studies have explored the significance of PSC in pancreatic neuroendocrine tumours (panNET). Their contribution to the fibrotic responses in panNET remains poorly understood. How PSC promote tumorigenesis and differentiation in panNET after being activated to myofibroblasts or cancer-associated fibroblasts (CAF) has not been studied.

Conference:

Presenting Author: Tang Q

Authors: Liu J, Li X, Bai J, Tang Q,

Keywords: caf, stellate cell, pan NET, Oncogenes,

#4062 Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine neoplasms (NEN)

Introduction: VTE is a significant complication in oncology and one of the primary causes of cancer-related mortality. Few studies have addressed VTE in pts with NEN, with an estimated incidence of 7.5% in the literature. Nevertheless, there is no evidence from large datasets.

Conference:

Presenting Author:

Authors: Hernando Cubero J, Gutierrez-Gordo M, Roca-Herrera M, García-Álvarez A, Serradell S,

Keywords: Thrombosis, Heparin, Splenic thrombosis,

#3999 Exploring the biological and clinical heterogeneity of grade 2 pancreatic neuroendocrine tumors: Insights into diagnosis, prognosis, and therapeutic targets

Introduction: Pancreatic neuroendocrine neoplasms (PanNENs) show heterogeneous behavior, mainly related to their grade (G), nevertheless small well-differentiated G1 and G2 lesions are usually approached the same conservative way.

Conference:

Presenting Author:

Authors: Gallo C, Lorenzo Andrea C, Pietro I, Sara M,

Keywords: pancreas, neuroendocrine, survival, grading,

#3403 Trends in chemotherapy use in neuroendocrine neoplasms: One step beyond guidelines

Introduction: The therapeutic landscape of neuroendocrine neoplasms (NENs) is constantly evolving. Current guidelines reflect the complexity of treatment sequences and mainly incorporate evidence from phase 3 clinical trials. Chemotherapy (CT) is a valuable option for patients with lung, pancreatic, and high-grade NENs, but proper phase 3 randomized studies are an unmet need. Nevertheless, several phase 2 studies with CT have been presented and published in the last year, with impact in both clinical practice and guidelines.

Conference:

Presenting Author:

Authors: Hernando J, Garcia-Diaz H, Bellas Fernandez L, Garcia Alvarez A, Roca M,

Keywords: Chemotherapy, CAPTEM, GUIDELINES,

#3275 MicroRNA prognostic signature in neuroendocrine neoplasias (NENs) of lung and GEP origin: In silico analysis of target genes and pathways

Introduction: Molecular knowledge of NENs has increased in the last years. Nevertheless, the lack of in vivo models makes it difficult to guide functional experiments to better understand the biological implications of described molecular alterations. In this context, and as miRNAs contribute to regulate gene expression, we performed an in silico analysis to explore target genes and involved pathways regulated by an 8-miRNA prognostic signature that we recently developed in NENs, that stratified patients in 3 prognostic groups (Espinosa-Olarte P et al, ESMO 2020).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Espinosa Olarte P, Soldevilla B, Carretero-Puche C, Molina-Pinelo S, Robles C,

Keywords: neuroendocrine neoplasia, miRNAs, genes, pathways, prognosis,